Sarepta Therapeutics, Inc. (0L35.L)
USD 122.56
(-2.47%)
USD 122.56
(-2.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.09 Billion USD | 37.83% |
| 2022 | 793.02 Million USD | 31.11% |
| 2021 | 604.83 Million USD | 26.88% |
| 2020 | 476.71 Million USD | 47.02% |
| 2019 | 324.24 Million USD | 21.51% |
| 2018 | 266.84 Million USD | 81.24% |
| 2017 | 147.23 Million USD | 2682.67% |
| 2016 | 5.29 Million USD | 103.65% |
| 2015 | -144.94 Million USD | -71.84% |
| 2014 | -84.34 Million USD | -10.89% |
| 2013 | -76.06 Million USD | -420.85% |
| 2012 | -14.6 Million USD | -232.01% |
| 2011 | 11.06 Million USD | 463.86% |
| 2010 | 1.96 Million USD | -88.84% |
| 2009 | 17.58 Million USD | -17.28% |
| 2008 | 21.25 Million USD | 93.52% |
| 2007 | 10.98 Million USD | 9428.23% |
| 2006 | 115.29 Thousand USD | -97.59% |
| 2005 | 4.78 Million USD | 1011.31% |
| 2004 | 430.46 Thousand USD | -55.62% |
| 2003 | 969.86 Thousand USD | 15.9% |
| 2002 | 836.78 Thousand USD | 18.51% |
| 2001 | 706.1 Thousand USD | -58.8% |
| 2000 | 1.71 Million USD | 1613.84% |
| 1999 | 100 Thousand USD | -75.0% |
| 1998 | 400 Thousand USD | -33.33% |
| 1997 | 600 Thousand USD | 0.0% |
| 1996 | 600 Thousand USD | 500.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 362.9 Million USD | 2.92% |
| 2024 Q2 | 309.66 Million USD | -14.67% |
| 2023 Q2 | 227.11 Million USD | 3.95% |
| 2023 Q4 | 352.6 Million USD | 19.61% |
| 2023 Q3 | 294.79 Million USD | 29.8% |
| 2023 FY | 1.09 Billion USD | 37.83% |
| 2023 Q1 | 218.48 Million USD | -4.02% |
| 2022 Q3 | 190.31 Million USD | -2.75% |
| 2022 FY | 793.02 Million USD | 31.11% |
| 2022 Q4 | 227.62 Million USD | 19.6% |
| 2022 Q1 | 179.38 Million USD | 5.7% |
| 2022 Q2 | 195.69 Million USD | 9.09% |
| 2021 Q4 | 169.71 Million USD | 2.26% |
| 2021 Q1 | 124.58 Million USD | 1.51% |
| 2021 Q2 | 144.57 Million USD | 16.04% |
| 2021 FY | 604.83 Million USD | 26.88% |
| 2021 Q3 | 165.96 Million USD | 14.79% |
| 2020 Q3 | 128.9 Million USD | 3.94% |
| 2020 FY | 476.71 Million USD | 47.02% |
| 2020 Q1 | 101.05 Million USD | 19.52% |
| 2020 Q2 | 124.02 Million USD | 22.73% |
| 2020 Q4 | 122.73 Million USD | -4.79% |
| 2019 Q3 | 86 Million USD | 9.21% |
| 2019 Q1 | 74.94 Million USD | 5.15% |
| 2019 Q2 | 78.74 Million USD | 5.07% |
| 2019 Q4 | 84.54 Million USD | -1.7% |
| 2019 FY | 324.24 Million USD | 21.51% |
| 2018 Q1 | 59.02 Million USD | 9.85% |
| 2018 Q4 | 71.28 Million USD | 2.2% |
| 2018 Q3 | 69.74 Million USD | 4.42% |
| 2018 FY | 266.84 Million USD | 81.24% |
| 2018 Q2 | 66.79 Million USD | 13.17% |
| 2017 Q4 | 53.73 Million USD | 25.32% |
| 2017 FY | 147.23 Million USD | 2682.67% |
| 2017 Q3 | 42.87 Million USD | 24.36% |
| 2017 Q2 | 34.47 Million USD | 114.28% |
| 2017 Q1 | 16.09 Million USD | 204.1% |
| 2016 Q4 | 5.29 Million USD | 115.76% |
| 2016 Q2 | -43.83 Million USD | -14.39% |
| 2016 FY | 5.29 Million USD | 103.65% |
| 2016 Q1 | -38.32 Million USD | 4.01% |
| 2016 Q3 | -33.57 Million USD | 23.4% |
| 2015 FY | -144.94 Million USD | -71.84% |
| 2015 Q4 | -39.92 Million USD | -8.87% |
| 2015 Q3 | -36.67 Million USD | -25.68% |
| 2015 Q2 | -29.18 Million USD | 52.83% |
| 2015 Q1 | -61.86 Million USD | -101.66% |
| 2014 FY | -84.34 Million USD | -10.89% |
| 2014 Q2 | -27.68 Million USD | -45.47% |
| 2014 Q3 | -32.61 Million USD | -17.8% |
| 2014 Q4 | -30.67 Million USD | 5.94% |
| 2014 Q1 | -19.03 Million USD | 11.62% |
| 2013 Q2 | -14.13 Million USD | -57.28% |
| 2013 Q3 | -20.76 Million USD | -46.89% |
| 2013 Q4 | -21.53 Million USD | -3.71% |
| 2013 Q1 | -8.98 Million USD | -66.51% |
| 2013 FY | -76.06 Million USD | -420.85% |
| 2012 FY | -14.6 Million USD | -232.01% |
| 2012 Q1 | 4.33 Million USD | -68.07% |
| 2012 Q2 | 5.65 Million USD | 30.24% |
| 2012 Q3 | 669 Thousand USD | -88.16% |
| 2012 Q4 | -5.39 Million USD | -906.88% |
| 2011 Q3 | -3.74 Million USD | -132.34% |
| 2011 Q1 | 8.76 Million USD | 173.4% |
| 2011 Q4 | 13.58 Million USD | 462.56% |
| 2011 Q2 | 11.58 Million USD | 32.17% |
| 2011 FY | 11.06 Million USD | 463.86% |
| 2010 Q1 | -6.53 Million USD | -227.02% |
| 2010 FY | 1.96 Million USD | -88.84% |
| 2010 Q2 | -3.67 Million USD | 43.8% |
| 2010 Q3 | 4.9 Million USD | 233.65% |
| 2010 Q4 | -11.94 Million USD | -343.45% |
| 2009 FY | 17.58 Million USD | -17.28% |
| 2009 Q3 | 3.42 Million USD | 16.3% |
| 2009 Q4 | 5.14 Million USD | 50.1% |
| 2009 Q2 | 2.94 Million USD | -6.51% |
| 2009 Q1 | 3.15 Million USD | -42.52% |
| 2008 FY | 21.25 Million USD | 93.52% |
| 2008 Q3 | 5.17 Million USD | 3.77% |
| 2008 Q2 | 4.98 Million USD | -11.41% |
| 2008 Q1 | 5.62 Million USD | 8.45% |
| 2008 Q4 | 5.47 Million USD | 5.98% |
| 2007 Q2 | 2.35 Million USD | 338.66% |
| 2007 FY | 10.98 Million USD | 9428.23% |
| 2007 Q4 | 5.18 Million USD | 78.14% |
| 2007 Q3 | 2.91 Million USD | 23.81% |
| 2007 Q1 | 536.04 Thousand USD | 2959.78% |
| 2006 FY | 115.29 Thousand USD | -97.59% |
| 2006 Q4 | 17.51 Thousand USD | 32.2% |
| 2006 Q3 | 13.25 Thousand USD | -28.59% |
| 2006 Q2 | 18.55 Thousand USD | -71.87% |
| 2006 Q1 | 65.96 Thousand USD | -95.35% |
| 2005 Q2 | 39.31 Thousand USD | -13.0% |
| 2005 Q1 | 45.19 Thousand USD | -84.18% |
| 2005 Q4 | 1.41 Million USD | -56.81% |
| 2005 Q3 | 3.28 Million USD | 8247.04% |
| 2005 FY | 4.78 Million USD | 1011.31% |
| 2004 FY | 430.46 Thousand USD | -55.62% |
| 2004 Q3 | 9151.00 USD | -74.77% |
| 2004 Q4 | 285.58 Thousand USD | 3020.84% |
| 2004 Q2 | 36.27 Thousand USD | -63.53% |
| 2004 Q1 | 99.45 Thousand USD | -26.43% |
| 2003 Q1 | 257.92 Thousand USD | 52.43% |
| 2003 Q4 | 135.18 Thousand USD | -67.38% |
| 2003 FY | 969.86 Thousand USD | 15.9% |
| 2003 Q2 | 162.41 Thousand USD | -37.03% |
| 2003 Q3 | 414.35 Thousand USD | 155.13% |
| 2002 Q4 | 169.2 Thousand USD | -27.13% |
| 2002 Q1 | 237.69 Thousand USD | -19.51% |
| 2002 Q2 | 197.69 Thousand USD | -16.83% |
| 2002 Q3 | 232.19 Thousand USD | 17.45% |
| 2002 FY | 836.78 Thousand USD | 18.51% |
| 2001 Q4 | 295.3 Thousand USD | -3.98% |
| 2001 FY | 706.1 Thousand USD | -58.8% |
| 2001 Q3 | 307.54 Thousand USD | 252.44% |
| 2001 Q2 | 87.26 Thousand USD | 446.08% |
| 2001 Q1 | 15.98 Thousand USD | -92.26% |
| 2000 Q3 | 208.69 Thousand USD | 121.5% |
| 2000 Q2 | 94.22 Thousand USD | -92.18% |
| 2000 FY | 1.71 Million USD | 1613.84% |
| 2000 Q1 | 1.2 Million USD | 0.0% |
| 2000 Q4 | 206.32 Thousand USD | -1.13% |
| 1999 Q1 | 200 Thousand USD | 100.0% |
| 1999 FY | 100 Thousand USD | -75.0% |
| 1999 Q3 | 200 Thousand USD | 100.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q2 | 100 Thousand USD | -50.0% |
| 1998 Q2 | 200 Thousand USD | 0.0% |
| 1998 FY | 400 Thousand USD | -33.33% |
| 1998 Q4 | 100 Thousand USD | -50.0% |
| 1998 Q3 | 200 Thousand USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | 0.0% |
| 1997 Q1 | 200 Thousand USD | 1900.0% |
| 1997 Q2 | 300 Thousand USD | 50.0% |
| 1997 Q3 | 100 Thousand USD | -66.67% |
| 1997 FY | 600 Thousand USD | 0.0% |
| 1997 Q4 | 200 Thousand USD | 100.0% |
| 1996 Q3 | 20 Thousand USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q4 | 10 Thousand USD | -50.0% |
| 1996 FY | 600 Thousand USD | 500.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 1198.176% |
| Dynavax Technologies Corporation | 182.11 Million USD | -500.16% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -108.689% |
| Perrigo Company plc | 1.68 Billion USD | 34.956% |
| Illumina, Inc. | 2.74 Billion USD | 60.168% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 92.821% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 11525.81% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 95.879% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 79.137% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -10784.216% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 90.329% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 5648.469% |
| Waters Corporation | 1.76 Billion USD | 37.94% |
| Biogen Inc. | 7.3 Billion USD | 85.032% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 2511.457% |
| Evolus, Inc. | 140.52 Million USD | -677.787% |
| Adicet Bio, Inc. | -6.09 Million USD | 18023.795% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -7288.083% |
| bluebird bio, Inc. | -4.03 Million USD | 27221.414% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -1395.878% |
| FibroGen, Inc. | 128.9 Million USD | -747.912% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 68.456% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 3606.818% |
| Homology Medicines, Inc. | -7.22 Million USD | 15219.56% |
| Geron Corporation | -123.5 Million USD | 984.993% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 27.992% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -201.907% |
| Myriad Genetics, Inc. | 476.4 Million USD | -129.428% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 374412.671% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 374.075% |
| Zoetis Inc. | 5.83 Billion USD | 81.265% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -361818.212% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 49.61% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 42.606% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 87.301% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 360823.762% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -40.395% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 349299.042% |
| Verastem, Inc. | -62 Thousand USD | 1762991.935% |
| Nektar Therapeutics | 53.47 Million USD | -1943.818% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -346.968% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 1382.615% |
| OPKO Health, Inc. | 318.12 Million USD | -243.571% |
| Exelixis, Inc. | 1.75 Billion USD | 37.815% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 40.836% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -129.672% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -49245.056% |
| Imunon, Inc. | -720 Thousand USD | 151903.529% |
| Blueprint Medicines Corporation | 236.58 Million USD | -361.989% |
| Insmed Incorporated | 239.63 Million USD | -356.107% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -71.614% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -6210.948% |
| TG Therapeutics, Inc. | 219.1 Million USD | -398.838% |
| Incyte Corporation | 3.44 Billion USD | 68.233% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -217.823% |